Anti-SN38 Antibody [PSH0-06]
HA721259
ApplicationsWestern Blot, ELISA
Product group Antibodies
Overview
- SupplierHUABIO
- Product NameAnti-SN38 Antibody [PSH0-06]
- Delivery Days Customer2
- ApplicationsWestern Blot, ELISA
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDPSH0-06
- Concentration1 mg/ml
- ConjugateUnconjugated
- HostRabbit
- IsotypeIgG
- Scientific DescriptionSN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan. SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 microM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC41116161